Market Research Logo

Endometrial Cancer - Pipeline Review, H1 2015

Introduction
Global Markets Direct Report Coverage
Endometrial Cancer Overview
Therapeutics Development
Pipeline Products for Endometrial Cancer - Overview
Pipeline Products for Endometrial Cancer - Comparative Analysis
Endometrial Cancer - Therapeutics under Development by Companies
Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes
Endometrial Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Endometrial Cancer - Products under Development by Companies
Endometrial Cancer - Products under Investigation by Universities/Institutes
Endometrial Cancer - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Aeterna Zentaris Inc.
Ariad Pharmaceuticals, Inc.
Arno Therapeutics, Inc.
ArQule, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc.
Boehringer Ingelheim GmbH
Critical Outcome Technologies Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Esperance Pharmaceuticals, Inc.
Exelixis, Inc.
Farmsintez
Galena Biopharma, Inc.
Genentech, Inc.
Genmab A/S
GlaxoSmithKline Plc
Gradalis Inc.
ImmunoGen, Inc.
Incyte Corporation
Karyopharm Therapeutics, Inc.
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Novartis AG
OncoHoldings, Inc.
Oncothyreon Inc.
Otsuka Holdings Co., Ltd.
Pharma Mar, S.A.
Puma Biotechnology, Inc.
Sanofi
Scancell Holdings Plc
Shenogen Pharma Group Ltd.
Endometrial Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(ponatinib hydrochloride + ridaforolimus) - Drug Profile
²¹²Pb-TCMC-Trastuzumab - Drug Profile
AEZS-125 - Drug Profile
afuresertib hydrochloride + trametinib dimethyl sulfoxide - Drug Profile
ARQ-092 - Drug Profile
AV-203 - Drug Profile
AZD-2014 - Drug Profile
AZD-5363 - Drug Profile
buparlisib hydrochloride - Drug Profile
cabozantinib s-malate - Drug Profile
cancer vaccine - Drug Profile
Cell Therapy for Oncology - Drug Profile
CLR-457 - Drug Profile
COTI-2 - Drug Profile
cridanimod - Drug Profile
dalantercept - Drug Profile
EP-200 - Drug Profile
epacadostat - Drug Profile
everolimus - Drug Profile
FROST-450 - Drug Profile
GALE-301 - Drug Profile
GDC-0927 - Drug Profile
GSK-2636771 - Drug Profile
HO-3867 - Drug Profile
HuMax-TF-ADC - Drug Profile
INCB-54828 - Drug Profile
lenvatinib - Drug Profile
lurbinectedin - Drug Profile
mirvetuximab soravtansine - Drug Profile
MK-2206 - Drug Profile
Modi-1 - Drug Profile
Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - Drug Profile
neratinib - Drug Profile
nintedanib - Drug Profile
onapristone ER - Drug Profile
ONCO-101 - Drug Profile
ONT-10 - Drug Profile
OPB-111001 - Drug Profile
patritumab - Drug Profile
Peptides to Inhibit GnRH II Receptor for Oncology - Drug Profile
pimasertib hydrochloride + voxtalisib - Drug Profile
sapanisertib - Drug Profile
SAR-408701 - Drug Profile
selinexor - Drug Profile
SERD-2 - Drug Profile
SNG-1153 - Drug Profile
talazoparib - Drug Profile
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
zoptarelin doxorubicin - Drug Profile
Endometrial Cancer - Recent Pipeline Updates
Endometrial Cancer - Dormant Projects
Endometrial Cancer - Discontinued Products
Endometrial Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Endometrial Cancer, H1 2015
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Endometrial Cancer - Pipeline by Acceleron Pharma, Inc., H1 2015
Endometrial Cancer - Pipeline by Aeterna Zentaris Inc., H1 2015
Endometrial Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2015
Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H1 2015
Endometrial Cancer - Pipeline by ArQule, Inc., H1 2015
Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2015
Endometrial Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Endometrial Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2015
Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2015
Endometrial Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Endometrial Cancer - Pipeline by Eisai Co., Ltd., H1 2015
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2015
Endometrial Cancer - Pipeline by Exelixis, Inc., H1 2015
Endometrial Cancer - Pipeline by Farmsintez, H1 2015
Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H1 2015
Endometrial Cancer - Pipeline by Genentech, Inc., H1 2015
Endometrial Cancer - Pipeline by Genmab A/S, H1 2015
Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015
Endometrial Cancer - Pipeline by Gradalis Inc., H1 2015
Endometrial Cancer - Pipeline by ImmunoGen, Inc., H1 2015
Endometrial Cancer - Pipeline by Incyte Corporation, H1 2015
Endometrial Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Endometrial Cancer - Pipeline by Merck & Co., Inc., H1 2015
Endometrial Cancer - Pipeline by Merck KGaA, H1 2015
Endometrial Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Endometrial Cancer - Pipeline by Novartis AG, H1 2015
Endometrial Cancer - Pipeline by OncoHoldings, Inc., H1 2015
Endometrial Cancer - Pipeline by Oncothyreon Inc., H1 2015
Endometrial Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Endometrial Cancer - Pipeline by Pharma Mar, S.A., H1 2015
Endometrial Cancer - Pipeline by Puma Biotechnology, Inc., H1 2015
Endometrial Cancer - Pipeline by Sanofi, H1 2015
Endometrial Cancer - Pipeline by Scancell Holdings Plc, H1 2015
Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Endometrial Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Endometrial Cancer - Dormant Projects, H1 2015
Endometrial Cancer - Dormant Projects (Contd..1), H1 2015
Endometrial Cancer - Dormant Projects (Contd..2), H1 2015
Endometrial Cancer - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Endometrial Cancer, H1 2015
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Endometrial Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Endometrial Cancer - Pipeline Review, H1 2015’, provides an overview of the Endometrial Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Endometrial Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Endometrial Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;